Sun Pharma Q2 Results FY25 reported a 28% year-on-year growth in the consolidated net profit. On the Sun Pharma Q2 results date which was October 28, 2024, the Sun Pharma share price closed at ₹1,902.90. On October 29, 2024, Sun Pharma share price closed with a fall at ₹1,871.60. So, let’s get into the details of the pharma player’s Q2 FY25 revenue and segment earnings.
Sun Pharma Q2 Results FY25: Profit and Revenue
Sun Pharma share price has delivered negative returns of 1.65% in the last 1 day (as on October 29, 2024) amidst a rise in profits. The consolidated net profit was ₹3,040 crores in the second quarter of FY25 higher than the net profit of ₹2,375 crores in the sequential quarter of FY24.
The revenue from operations rose to ₹13,291 crores in Q2 FY25 with a growth of 9% YoY. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was ₹3,939 crores, showing a growth of 24% YoY, while the EBITDA margin was 29.6% in Q2 FY25.
Sun Pharma Q2 Results: Segment Performance
The sale of formulations in India rose by 11% YoY to ₹4,265 crores which constitutes 32% of the overall sales in Q2 FY25. The US formulations sales which constitute 33% of the total sales rose by 20% YoY to $517 million in the second quarter of FY25.
The sales in the emerging markets were at $293 million for the September quarter, up by 3% YoY. The sales of formulations in the rest of the world fell by 3% YoY to $199 million in Q2 FY25. In API (Active Pharmaceutical Ingredient), external sales grew by 7% YoY to ₹534 crores in Q2 FY25.
Conclusion
Sun Pharma Q2 results for FY25 highlighted that the company is focusing on increasing API supply. With a strong R&D expenditure, the company had entered into an agreement with Philogen to commercialize late-stage candidate Fibromun. Fibromun will help the company to expand its product portfolio for dermatologists. In the last 1-year, Sun Pharma share price has delivered a return of 68.42% (as on October 29, 2024).
Keep exploring stocks and open demat account with SMC Global Securities. Stay tuned for the upcoming Nifty 50 companies quarterly results.
Reference
https://sunpharma.com/wp-content/uploads/2024/10/Press-Release-Sun-Pharma-Q2FY25-Financial-Result.pdf
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
